Tuesday Mar 4
Takeda Pharmaceutical Co. Ltd. CEO Fesses Up To Blopress Mis-Marketing
Takeda's chief executive Yasuchika Hasegawa has admitted the company may have used "inappropriate" language in its marketing of blood pressure blockbuster Blopress, but denied any data falsification.
Global Atacand market: Latest market research analysed
It was launched for the treatment of hypertension in 1998 in the US, Europe, and Japan.